Madrigal Pharmaceuticals Inc (MDGL)
Official siteHEALTHCARE • BIOTECHNOLOGY • NASDAQ
Market Cap: $9.93B
Last updated: Nov 17, 2026 at 11:06 AM ET
Madrigal Pharmaceuticals Inc (MDGL) Stock Forecast
Analysts expect Madrigal Pharmaceuticals (MDGL) to earn -$2.00 per share in the fiscal year ending Dec 31, 2026, on revenue of $1.59B. Of 19 analysts, 18 rate the stock Buy or Strong Buy, 1 Hold and 0 Sell or Strong Sell, for a consensus of Buy. For the fiscal year ending Dec 31, 2027, the EPS consensus is $11.21.
Analyst Ratings
Scoring Strong Buy as 1 and Strong Sell as 5, the 19 ratings average 1.89, inside the Buy band from 1.5 up to 2.5. Buy and Strong Buy make up 95% of the ratings.
| Rating | Analysts | Share |
|---|---|---|
| Strong Buy | 3 | 15.8% |
| Buy | 15 | 78.9% |
| Hold | 1 | 5.3% |
| Sell | 0 | 0.0% |
| Strong Sell | 0 | 0.0% |
- Consensus
- Buy
- Total analysts
- 19
Price Target
Analyst price targets are part of paid GNG plans. See plans
Annual Estimates
From the first fiscal year below to the second, the EPS consensus turns from a loss to a profit and revenue estimates rise 37.7%.
- Fiscal year ending Dec 31, 2026
- -$2.00
- EPS consensus, revenue $1.59B
- Fiscal year ending Dec 31, 2027
- $11.21
- EPS consensus, revenue $2.19B
- Next report
- Feb 17, 2027
- Estimated
EPS range
Revenue range
| Fiscal year ending | EPS consensus | EPS range | EPS analysts | Revenue consensus | Revenue range | Rev. analysts |
|---|---|---|---|---|---|---|
| Dec 31, 2026 | -$2.00 | -$2.00 to -$2.00 | 1 | $1.59B | $1.57B to $1.61B | 17 |
| Dec 31, 2027 | $11.21 | $5.63 to $15.16 | 3 | $2.19B | $2.03B to $2.29B | 18 |
Quarterly Estimates
The EPS consensus falls from $1.14 for the quarter ending Dec 31, 2026 to $0.79 for the quarter ending Mar 31, 2027.
EPS range
Revenue range
| Quarter ending | EPS consensus | EPS range | EPS analysts | Revenue consensus | Revenue range | Rev. analysts |
|---|---|---|---|---|---|---|
| Dec 31, 2026 | $1.14 | -$0.34 to $2.80 | 20 | $481.19M | $431.94M to $528.15M | 19 |
| Mar 31, 2027 | $0.79 | -$0.39 to $1.97 | 2 | $459.01M | $425.14M to $468.40M | 11 |
Estimate Revisions
No EPS estimate for the 3 periods below was revised in the last 30 days.
| Period | Up 30 days | Down 30 days |
|---|---|---|
| Fiscal year ending Dec 31, 2026 | 0 | 0 |
| Fiscal year ending Dec 31, 2027 | 0 | 0 |
| Quarter ending Mar 31, 2027 | 0 | 0 |
EPS Trend
Over the last 90 days, the EPS consensus for the fiscal year ending Dec 31, 2026 has improved from -$6.49.
| Period | Now | 7 days ago | 30 days ago | 60 days ago | 90 days ago | Change |
|---|---|---|---|---|---|---|
| Fiscal year ending Dec 31, 2026 | -$2.00 | -$6.32 | -$6.49 | -$6.49 | -$6.49 | N/A |
| Fiscal year ending Dec 31, 2027 | $11.21 | $9.42 | $9.63 | $9.63 | $9.63 | +16.5% |
| Quarter ending Mar 31, 2027 | $0.79 | $0.32 | -$0.76 | -$0.76 | -$0.76 | N/A |
Frequently Asked Questions About MDGL
What is the MDGL stock forecast?
Consensus analyst estimates put Madrigal Pharmaceuticals's EPS at -$2.00 for the fiscal year ending Dec 31, 2026, on revenue of $1.59B. The consensus rating from 19 analysts is Buy.
How do analysts rate MDGL stock?
Of 19 analysts covering Madrigal Pharmaceuticals, 3 rate it Strong Buy, 15 Buy, 1 Hold, 0 Sell and 0 Strong Sell, for a consensus of Buy.
What EPS do analysts expect from MDGL next year?
For the fiscal year ending Dec 31, 2026, the consensus EPS estimate is -$2.00, with estimates from -$2.00 to -$2.00 from 1 analyst. For the fiscal year ending Dec 31, 2027, the consensus EPS estimate is $11.21, with estimates from $5.63 to $15.16 from 3 analysts.
What revenue do analysts expect from Madrigal Pharmaceuticals next year?
For the fiscal year ending Dec 31, 2026, the consensus revenue estimate is $1.59B, with estimates from $1.57B to $1.61B. For the fiscal year ending Dec 31, 2027, the consensus revenue estimate is $2.19B, with estimates from $2.03B to $2.29B.
How many analysts cover MDGL?
19 analysts rate Madrigal Pharmaceuticals stock, and 1 analyst estimates its EPS for the fiscal year ending Dec 31, 2026.
MDGL pages: Overview, Earnings, Forecast, Financials, Valuation, Competitors, Government Contracts